TY - JOUR
T1 - Nicotinic acid derivative (xanthinol nicotinate) induced bullous eruption
AU - Khan, S.A.
AU - Rodrigues, G.
AU - Rao, P.G.M.
N1 - Cited By :3
Export Date: 10 November 2017
CODEN: IJMDE
Correspondence Address: Khan, S.A.; Faculty and Research Scholar, Dept. of Pharmacy Practice, S S Cancer Hospital and Research Centre, Manipal-576 104, Karnataka, India; email: [email protected]
Chemicals/CAS: acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; cilostazol, 73963-72-1; nicotinic acid, 54-86-4, 59-67-6; xanthinol nicotinate, 437-74-1
Tradenames: aspirin; complamina
References: ASHP therapeutic position statement on the safe use of niacin in the management of dyslipidemias (1997) Am. J. Health Syst. Pharm., 54, pp. 2815-2819; Davis, E., Rozov, H., Xanthinol nicotinate in peripheral vascular disease (1975) Practitioner, 215, pp. 793-798; Ganzer, B.M., Langzeitstudie zu acipimox (1990) Pharmazie, 135, p. 31; Goldberg, A.C., Clinical trial experience with extended-release niacin (Niaspan): Dose-escalation study (1998) Am. J. Cardiol., 82, pp. 35U-38U; Hartwig, S.C., Siegel, J., Schneider, P.J., Preventability and severity assessment in reporting adverse drug reactions (1992) Am. J. Hosp. Pharm., 49, pp. 2229-2232; Lehmann, E., Van Der Crone, L., Grobe-Einsler, R., Linden, M., Drug monitoring study (phase IV) of xantinol nicotinate (Complamin) in general practice (1993) Pharmacopsychiatry, 26, pp. 42-48; Luria, M.H., Atherosclerosis: The importance of HDL cholesterol and prostacyclin: A role for niacin therapy (1990) Med. Hypothesis, 31, pp. 21-28; Miller, S.M., Potential perils of niacin therapy (1991) Clin. Lab. Sci., 4, pp. 156-158; Morgan, J.M., Capuzzi, D.M., Guyton, J.R., A new extended-release niacin (Niaspan): Efficacy, tolerability, and safety in hypercholesterolemic patients (1998) Am. J. Cardiol., 82, pp. 29-34; Naranjo, C.A., Busto, U., Sellers, E.M., Sandor, P., Ruiz, I., Roberts, E.A., Janecek, E., Greenblatt, D.J., A method for estimating the probability of adverse drug reaction (1981) Clin. Pharmacol. Therapeutics, 30, pp. 239-245; (1990) Facts and Comparisons, , B. Olin, ed., Facts and Comparison, Inc, St Louis, MO; Prosser, T.R., Kamysz, P.L., Multidisciplinary adverse drug reaction surveillance (1990) Am. J. Hosp. Pharm., 47, pp. 1334-1339; Verhaeghe, R., Drugs acting on the cerebral and peripheral circulations and drugs used in the treatment of migraine (2000) Meyler's Side Effects of Drugs, pp. 629-630. , M.N.G. Dukes and K. Aronson, eds, Elsevier Publication, Amsterdam; Vrhovac, B., Drugs affecting lipid metabolism (2000) Meyler's Side Effects of Drugs, pp. 1527-1535. , M.N.G. Dukes and K. Aronson, eds, Elsevier Publication, Amsterdam
PY - 2006
Y1 - 2006
N2 - Xantinol nicotinate, a nicotinic acid derivative is used in the management of peripheral and cerebral vascular disorders and in hyperlipidaemias for over 40 years. Nicotinic acid derivatives have been associated with dermatological adverse effects. Flushing is claimed to be less frequent than with nicotinic acid, but has nevertheless been repeatedly observed. We present here a case of bullous eruptions due to xanthinol nicotinate, a probable reaction according to the Naranjo Adverse Drug Reaction Probability Scale. © 2006 - IOS Press and the authors. All rights reserved.
AB - Xantinol nicotinate, a nicotinic acid derivative is used in the management of peripheral and cerebral vascular disorders and in hyperlipidaemias for over 40 years. Nicotinic acid derivatives have been associated with dermatological adverse effects. Flushing is claimed to be less frequent than with nicotinic acid, but has nevertheless been repeatedly observed. We present here a case of bullous eruptions due to xanthinol nicotinate, a probable reaction according to the Naranjo Adverse Drug Reaction Probability Scale. © 2006 - IOS Press and the authors. All rights reserved.
M3 - Article
SN - 0924-6479
VL - 18
SP - 159
EP - 162
JO - International Journal of Risk and Safety in Medicine
JF - International Journal of Risk and Safety in Medicine
IS - 3
ER -